Pharmaceutical composition, compound preparation and enteric-coated tablet
By combining bromelain with microcrystalline cellulose 200, combined with other auxiliary materials and coating materials, the problems of deterioration and activity of bromelain preparations are solved, and high titer and stable enteric-coated tablet preparation is achieved, which is suitable for industrial production. and long-term use.
Patent Information
- Application Number
- CN202411233002.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2024-11-22
AI Technical Summary
Existing bromelain preparations are prone to discoloration and yellowing, their activity decreases, their titer decreases, and their shelf life is short, resulting in high cost and low pass rate.
The composition of bromelain and microcrystalline cellulose 200 is used to form a compound preparation by adding silica, cross-linked povidone, corn starch and magnesium stearate, and coated with polyacrylic resin. Prepare enteric-coated tablets to improve stability and titer.
It significantly improves the stability and titer of bromelain tablets, and can still maintain a titer of 98.5% after long-term storage, making it suitable for industrial production.
Smart Images

Figure SMS_1
Abstract
Description
Technical Field
[0001] The invention relates to the field of medicines, in particular to a medicine composition, a compound preparation and an enteric-coated tablet. Background Art
[0002] Bromelain is a plant protease extracted from the stem, leaf and skin of pineapple fruit, and obtained by refining, purification, concentration, enzyme immobilization and freeze drying. It has been widely used in the food and pharmaceutical industries. Bromelain tablets have been used in various clinical applications, mainly bromelain enteric-coated tablets, bromelain enteric-coated capsules, asparagus bromelain capsules, compound bromelain enteric-coated tablets, and other compound tablets containing bromelain. However, the current bromelain preparation products are prone to discoloration and yellowing, reduced potency, unclear efficacy, and reduced potency during production. The main reasons include that the existing preparation process will greatly reduce the activity of bromelain during granulation and tableting, and the instability of bromelain itself in application. It will deteriorate under long-term storage and its potency will continue to decline. Therefore, bromelain preparations have the disadvantages of high cost, low qualified rate and short shelf life. Summary of the invention
[0003] In view of this, the technical problem to be solved by the present invention is a pharmaceutical composition, a compound preparation and an enteric-coated tablet. The bromelain tablets made from the pharmaceutical composition provided by the present invention are not easy to deteriorate and can still maintain a high potency after a long time.
[0004] The present invention provides a pharmaceutical composition comprising the following components:
[0005] at least one of bromelain or a pharmaceutically acceptable salt thereof;
[0006] and microcrystalline cellulose type 200.
[0007] Specifically, the pharmaceutical composition of the present invention comprises the following components in parts by weight: 30 to 105 parts of at least one of bromelain or a pharmaceutically acceptable salt thereof; and 40 to 150 parts of microcrystalline cellulose 200 type.
[0008] The pharmaceutical composition of the present invention also includes 5 to 20 parts by mass of silicon dioxide. In certain embodiments of the present invention, the pharmaceutical composition of the present invention includes the following components in parts by mass: 30 to 105 parts of at least one of the forms of bromelain or a pharmaceutically acceptable salt thereof; 40 to 150 parts of microcrystalline cellulose 200 type; and 5 to 20 parts by mass of silicon dioxide. In one embodiment, the pharmaceutical composition of the present invention includes the following components in parts by mass: 35 parts of at least one of the forms of bromelain or a pharmaceutically acceptable salt thereof; 48 parts of microcrystalline cellulose 200 type; and 6 parts of silicon dioxide. In another embodiment, the pharmaceutical composition of the present invention includes the following components in parts by mass: 105 parts of at least one of the forms of bromelain or a pharmaceutically acceptable salt thereof; 120 parts of microcrystalline cellulose 200 type; and 15 parts of silicon dioxide.
[0009] The bromelain of the present invention is refined bromelain, and its heavy metal content is less than 3 ppm, its isoelectric point is greater than 9.5, and its average molecular weight is 33 kDa. The microcrystalline cellulose type 200 of the present invention is specifically microcrystalline cellulose of type 200 specification, which can be purchased in the market; microcrystalline cellulose is an important preparation auxiliary material, has filling properties, and can be used as a conventional filler for preparing tablets and capsules; has rheological properties, which can improve the rheological properties of the preparation and improve the quality of the preparation; has aesthetic properties, which can make the preparation more beautiful and increase the commercial value of the preparation.
[0010] The specifications of microcrystalline cellulose refer to the average diameter and particle size distribution range of microcrystalline particles. Commonly used specifications include type 20, type 101, type 102, type 200, and type 300. The application of microcrystalline cellulose of different specifications in preparations is also different. For example, type 20 and type 101 microcrystalline cellulose have very small molecular weights, low rheology and high wet strength, and small particle size, which can make the rheological properties of the preparations better, and have good tableting and coating properties for hard capsules, film coatings and tablets. Type 102 microcrystalline cellulose has a larger particle size and is easy to prepare into granules or spherical particles. It has good fluidity and filling properties and can be mixed with other preparation excipients when preparing tablets and capsules. Type 200 microcrystalline cellulose has a larger molecular weight and a larger particle size. It has higher rheology and lower wet strength, and has higher film-forming properties, water retention and mechanical strength. Type 300 microcrystalline cellulose has the largest particle size and is used in the preparation of sugar-coated preparations and micropills. It can improve the uniformity and stability of the preparation and make the preparation more beautiful.
[0011] The inventors of the present application creatively discovered that for the stabilization of bromelain, microcrystalline cellulose type 200, as an auxiliary material, plays a particularly excellent stabilizer or dispersant role after being mixed with bromelain, which can greatly improve the stability of bromelain tablets and effectively reduce the decrease in the activity of bromelain during the production process. The effect is far better than other specifications and types of microcrystalline cellulose.
[0012] The present invention also provides a compound preparation, which includes the following components: at least one of bromelain or its pharmaceutically acceptable salt forms; microcrystalline cellulose type 200; a glidant; a binder; a filler; and a lubricant. Specifically, it includes the following components: at least one of bromelain or its pharmaceutically acceptable salt forms; microcrystalline cellulose type 200; silicon dioxide; cross-linked polyvinylpyrrolidone; corn starch; and magnesium stearate. In the compound preparation of the present invention, the silicon dioxide acts as a glidant; the cross-linked polyvinylpyrrolidone acts as a binder; the corn starch acts as a filler; and the magnesium stearate acts as a lubricant. In the compound preparation of the present invention, the bromelain and the microcrystalline cellulose type 200 are the same as above and will not be repeated.
[0013] Specifically, the compound preparation of the present invention comprises the following components in parts by weight: 30 to 105 parts of bromelain or at least one of its pharmaceutically acceptable salt forms; 40 to 150 parts of microcrystalline cellulose 200 type; 0 to 400 parts of pig bile powder; 5 to 20 parts of silicon dioxide; 5 to 25 parts of cross-linked polyvinylpyrrolidone; 4 to 20 parts of corn starch; and 0.5 to 2 parts of magnesium stearate.
[0014] In one embodiment, the compound preparation of the present invention comprises the following components in parts by weight: 35 parts of at least one of bromelain or a pharmaceutically acceptable salt thereof; 48 parts of microcrystalline cellulose type 200; 5 parts of silicon dioxide; 6 parts of cross-linked polyvinylpyrrolidone; 4 parts of corn starch; and 0.5 parts of magnesium stearate.
[0015] In another embodiment, the compound preparation of the present invention comprises the following components in parts by weight: 105 parts of bromelain or at least one of its pharmaceutically acceptable salt forms; 102 parts of microcrystalline cellulose type 200; 15 parts of silicon dioxide; 15 parts of cross-linked polyvinylpyrrolidone; 12 parts of corn starch; and 1.5 parts of magnesium stearate.
[0016] In another embodiment, the compound preparation of the present invention comprises the following components in parts by weight: 40 parts of bromelain or at least one of its pharmaceutically acceptable salt forms; 40 parts of microcrystalline cellulose type 200; 400 parts of pig bile powder; 5 parts of silicon dioxide; 5 parts of cross-linked polyvinylpyrrolidone; 4 parts of corn starch; and 0.5 parts of magnesium stearate.
[0017] The present invention also provides an enteric-coated tablet, which comprises an active component and an enteric coating; the active component is the above-mentioned pharmaceutical composition or the above-mentioned compound preparation; the enteric coating is made of raw materials including polyacrylic acid resin (II), polyacrylic acid resin (III), talcum powder, castor oil, diethyl phthalate, polysorbate 80 and water. The enteric-coated tablet of the present invention is also called bromelain enteric-coated tablet; if other active components are added, it can be called compound bromelain enteric-coated tablet.
[0018] The present invention also provides a method for preparing the above-mentioned enteric-coated tablets, comprising the following steps: mixing the above-mentioned pharmaceutical composition or the above-mentioned compound preparation, tabletting, and coating with the above-mentioned enteric coating to obtain enteric-coated tablets. The present invention extracts the effective components in each raw material by adopting specific preparation steps, so that the effective components in each raw material are retained as much as possible. At the same time, the preparation method is simple and easy to implement, and is suitable for large-scale industrial production.
[0019] The present invention provides a pharmaceutical composition, a compound preparation and an enteric-coated tablet. The pharmaceutical composition, compound preparation and enteric-coated tablet provided by the present invention all include the following components: at least one of bromelain or a pharmaceutically acceptable salt thereof; and microcrystalline cellulose type 200. The pharmaceutical composition, compound preparation and enteric-coated tablet provided by the present invention can all be used to treat chronic gastroenteritis. The bromelain tablets made from the pharmaceutical composition provided by the present invention are not easy to deteriorate and can still maintain a high potency after a long time. Experiments show that the potency of the enteric-coated tablets provided by the present invention is as high as 115.1% (30,000 units / tablet), and the potency is 99.8% after an accelerated 6-month test, and the potency still reaches 98.5% after a long-term 24-month test, proving that it has good therapeutic effect and high stability. DETAILED DESCRIPTION
[0020] The present invention discloses a pharmaceutical composition, a compound preparation and an enteric-coated tablet. Those skilled in the art can refer to the contents of this article and appropriately improve the process parameters to achieve the above. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications of this article without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0021] The present invention will be further described below in conjunction with embodiments:
[0022] Example 1
[0023] 35 kg of bromelain, 48 kg of microcrystalline cellulose type 200, 6 kg of cross-linked polyvinylpyrrolidone, 4 kg of corn starch, 5 kg of silicon dioxide and 0.5 kg of magnesium stearate are fully mixed and compressed into tablets. Enteric coating materials, 3.3 kg of polyacrylic acid resin (II), 1.6 kg of polyacrylic acid resin (III), 3.6 kg of talc, 2.2 kg of castor oil, 0.48 kg of diethyl phthalate, 0.84 kg of polysorbate 80 and appropriate amount of purified water are used for coating.
[0024] The potency of the obtained prescription enteric-coated tablets (specification: 30,000 units / tablet) was measured in parallel 6 times (n=6), and the average value was taken. The content was calculated according to the labeled amount and was 115.1%.
[0025] Example 2
[0026] 105 kg of bromelain, 102 kg of microcrystalline cellulose type 200, 15 kg of cross-linked polyvinylpyrrolidone, 12 kg of corn starch, 15 kg of silicon dioxide and 1.5 kg of magnesium stearate are fully mixed and compressed into tablets. Enteric coating materials, 4.0 kg of polyacrylic acid resin (II), 2.0 kg of polyacrylic acid resin (III), 4.4 kg of talc, 3.0 kg of castor oil, 1.1 kg of diethyl phthalate, 1.9 kg of polysorbate 80 and appropriate amount of purified water are used for coating.
[0027] The potency of the obtained prescription enteric-coated tablets (specification: 100,000 units / tablet) was measured in parallel 6 times (n=6), and the average value was taken. The content was calculated according to the labeled amount and was 113.8%.
[0028] Example 3
[0029] 40 kg of protease, 400 kg of pig bile powder, 40 kg of microcrystalline cellulose type 200, 5 kg of cross-linked polyvinylpyrrolidone, 4 kg of corn starch, 5 kg of silicon dioxide and 0.5 kg of magnesium stearate are fully mixed and compressed into tablets. Enteric coating materials, 3.1 kg of polyacrylic acid resin (II), 1.2 kg of polyacrylic acid resin (III), 3.0 kg of talc, 2.0 kg of castor oil, 0.5 kg of diethyl phthalate, 0.9 kg of polysorbate 80 and appropriate amount of purified water are used for coating.
[0030] The potency of the obtained prescription compound enteric-coated tablets (specification: 30,000 units / tablet) was measured in parallel 6 times (n=6), and the average value was taken. The content was calculated according to the labeled amount and was 112.5%.
[0031] Comparative Example 1
[0032] 35 kg of bromelain, 41 kg of microcrystalline cellulose type 101, 6 kg of cross-linked polyvinylpyrrolidone, 4 kg of corn starch, 5 kg of silicon dioxide and 0.4 kg of magnesium stearate were fully mixed and tableted. Enteric coating materials, 3.3 kg of polyacrylic acid resin (II), 1.6 kg of polyacrylic acid resin (III), 3.6 kg of talc, 2.2 kg of castor oil, 0.48 kg of diethyl phthalate, 0.84 kg of polysorbate 80 and appropriate amount of purified water were used for coating.
[0033] The potency of the obtained prescription enteric-coated tablets (specification: 30,000 units / tablet) was measured in parallel 6 times (n=6), and the average value was taken. The content was calculated according to the labeled amount and was 113.4%.
[0034] The enteric-coated tablets of the above-mentioned Examples 1 to 3 and Comparative Example 1 were subjected to accelerated 6-month aging, long-term storage for 6 months, 12 months and 24 months of potency test, wherein the accelerated test conditions were: 40°C, RH75%; the long-term test conditions were: 25°C, RH60%; the results are shown in Table 1:
[0035] Table 1
[0036]
[0037] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.
Claims
1. A pharmaceutical composition, characterized in that Includes the following components: at least one of bromelain or a pharmaceutically acceptable salt thereof; and microcrystalline cellulose type 200.
2. The pharmaceutical composition according to claim 1, characterized in that The composition comprises the following components in parts by weight: 30-105 parts of at least one of bromelain or a pharmaceutically acceptable salt thereof; and 40-150 parts of microcrystalline cellulose type 200.
3. The pharmaceutical composition according to claim 2, characterized in that The pharmaceutical composition further comprises 5 to 20 parts by mass of silicon dioxide.
4. The pharmaceutical composition according to claim 3, characterized in that The composition comprises the following components in parts by weight: 35 parts of at least one of bromelain or a pharmaceutically acceptable salt thereof; 48 parts of microcrystalline cellulose type 200; and 6 parts of silicon dioxide; or, 105 parts of at least one of bromelain or a pharmaceutically acceptable salt thereof; 120 parts of microcrystalline cellulose type 200; and 15 parts of silicon dioxide.
5. The pharmaceutical composition according to claim 1, characterized in that The bromelain is refined bromelain, the heavy metal content of which is lower than 3 ppm, the isoelectric point of which is greater than 9.5, and the average molecular weight of which is 33 kDa.
6. A compound preparation, characterized in that: It includes the following components: at least one of bromelain or a pharmaceutically acceptable salt thereof; Microcrystalline cellulose type 200; Glidants; Adhesives; Fillers; and lubricants.
7. The compound preparation according to claim 6, characterized in that: It includes the following components in parts by weight: 30-105 parts of at least one of bromelain or a pharmaceutically acceptable salt thereof; 40-150 parts of microcrystalline cellulose type 200; 0~400 portions of pig bile powder; 5-20 parts of silicon dioxide; 5-25 parts of cross-linked polyvinylpyrrolidone; 4-20 parts corn starch; And 0.5~2 parts of magnesium stearate.
8. The compound preparation according to claim 7, characterized in that: It includes the following components in parts by weight: 35 parts of at least one of bromelain or a pharmaceutically acceptable salt thereof; 48 parts of microcrystalline cellulose type 200; 5 parts of silicon dioxide; 6 parts of crospovidone; 4 parts corn starch; and 0.5 parts of magnesium stearate; or, 105 parts of at least one of bromelain or a pharmaceutically acceptable salt thereof; 102 parts of microcrystalline cellulose type 200; 15 parts of silicon dioxide; 15 parts of crospovidone; 12 parts corn starch; and 1.5 parts of magnesium stearate; or, 40 parts of at least one of bromelain or a pharmaceutically acceptable salt thereof; 40 parts of microcrystalline cellulose type 200; 400 portions of pig bile powder; 5 parts of silicon dioxide; 5 parts of crospovidone; 4 parts corn starch; and 0.5 parts of magnesium stearate.
9. The compound preparation according to claim 8, characterized in that: The bromelain is refined bromelain, the heavy metal content of which is lower than 3 ppm, the isoelectric point of which is greater than 9.5, and the average molecular weight of which is 33 kDa.
10. An enteric-coated tablet, characterized in that: It includes an active ingredient and an enteric coating; The active ingredient is the pharmaceutical composition described in any one of claims 1 to 5 or the compound preparation described in any one of claims 6 to 9.
